Chinese Urokinase Manufacturers Optimize Virus Inactivation and Traceability to Meet International Standards

As global pharmaceutical regulatory authorities implement ICH Q14 requirements, Chinese urokinase raw material exports face stricter scrutiny on biological impurity safety and production traceability. Domestic manufacturers are optimizing virus inactivation processes and building full-chain urine collection traceability systems to meet international market access standards. Quality control now emphasizes validated viral safety, consistent specific activity, and ultra-low endotoxin levels to comply with USP and EP specifications.